Onyx Biotec IPO is a book built issue of Rs 29.34 crores. The issue is entirely a fresh issue of 48.1 lakh shares.
Onyx Biotec IPO bidding opened for subscription on November 13, 2024 and will close on November 18, 2024. The allotment for the Onyx Biotec IPO is expected to be finalized on Tuesday, November 19, 2024. Onyx Biotec IPO will list on NSE SME with tentative listing date fixed as Thursday, November 21, 2024.
Onyx Biotec IPO price band is set at ₹58 to ₹61 per share. The minimum lot size for an application is 2000 Shares. The minimum amount of investment required by retail investors is ₹122,000. The minimum lot size investment for HNI is 2 lots (4,000 shares) amounting to ₹244,000.
Horizon Management Private Limited is the book running lead manager of the Onyx Biotec IPO, while Mas Services Limited is the registrar for the issue. The market maker for Onyx Biotec IPO is Giriraj Stock Broking.
Refer to Onyx Biotec IPO RHP for detailed information.
Onyx Biotec IPO Details
| IPO Date | November 13, 2024 to November 18, 2024 |
| Listing Date | [.] |
| Face Value | ₹10 per share |
| Price Band | ₹58 to ₹61 per share |
| Lot Size | 2000 Shares |
| Total Issue Size | 4,810,000 shares (aggregating up to ₹29.34 Cr) |
| Fresh Issue | 4,810,000 shares (aggregating up to ₹29.34 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | NSE SME |
| Share holding pre issue | 13,322,200 |
| Share holding post issue | 18,132,200 |
| Market Maker portion | 244,000 shares Giriraj Stock Broking |
Onyx Biotec IPO Reservation
Onyx Biotec IPO offers 48,10,000 shares. 9,12,000 (18.96%) to QIB, 6,88,000 (14.3%) to NII, 16,00,000 (33.26%) to RII and 13,66,000 (28.4%) to Anchor investors.
| Investor Category | Shares Offered |
|---|---|
| Anchor Investor Shares Offered | 13,66,000 (28.4%) |
| Market Maker Shares Offered | 2,44,000 (5.07%) |
| QIB Shares Offered | 9,12,000 (18.96%) |
| NII (HNI) Shares Offered | 6,88,000 (14.3%) |
| Retail Shares Offered | 16,00,000 (33.26%) |
| Total Shares Offered | 48,10,000 (100%) |
Onyx Biotec IPO Anchor Investors Details
Onyx Biotec IPO raises Rs 8.33 crore from anchor investors. Onyx Biotec IPO Anchor bid date is November 12, 2024. Onyx Biotec IPO Anchor Investors list
| Bid Date | November 12, 2024 |
| Shares Offered | 1,366,000 |
| Anchor Portion Size (In Cr.) | 8.33 |
| Anchor lock-in period end date for 50% shares (30 Days) | December 19, 2024 |
| Anchor lock-in period end date for remaining shares (90 Days) | February 17, 2025 |
Onyx Biotec IPO Timeline (Tentative Schedule)
Onyx Biotec IPO opens on November 13, 2024, and closes on November 18, 2024.
| IPO Open Date | Wednesday, November 13, 2024 |
| IPO Close Date | Monday, November 18, 2024 |
| Basis of Allotment | Tuesday, November 19, 2024 |
| Initiation of Refunds | Wednesday, November 20, 2024 |
| Credit of Shares to Demat | Wednesday, November 20, 2024 |
| Listing Date | Thursday, November 21, 2024 |
| Cut-off time for UPI mandate confirmation | 5 PM on November 18, 2024 |
Onyx Biotec IPO Lot Size
Investors can bid for a minimum of 2000 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 2000 | ₹122,000 |
| Retail (Max) | 1 | 2000 | ₹122,000 |
| HNI (Min) | 2 | 4,000 | ₹244,000 |
| Lot Size Calculator | |||
Onyx Biotec IPO Promoter Holding
The Promoters of the company are Sanjay Jain, Naresh Kumar and Fateh Pal Singh.
| Share Holding Pre Issue | 88.60% |
| Share Holding Post Issue |
About Onyx Biotec Limited
Incorporated in May 2005, Onyx Biotec Limited is a pharmaceutical company providing sterile water for injections. The company currently manufactures Sterile Water for Injections and serves as a pharmaceutical contract manufacturer, offering a comprehensive range of Dry Powder Injections and Dry Syrups for both the Indian and overseas markets.
The company has two manufacturing units in Solan, Himachal Pradesh. Unit I has a daily production capacity of 638,889 units of Sterile Water for Injections, while Unit II produces 40,000 units of dry powder injections and 26,667 units of dry syrup per day in a single shift.
The company clientele includes Hetero Healthcare Limited, Mankind Pharma Limited, Sun Pharmaceutical Industries Limited, Aristo Pharmaceuticals Private Limited, Macleods Pharmaceuticals Limited, Mapra Laboratories Private Limited, Axa Parenterals Limited, FDC Limited, Zuventus Healthcare Limited, Akums Drugs and Pharmaceuticals Limited, Reliance Life Sciences Limited, among others.
As of May 31, 2024, the company had a client base of more than 100 Indian and multinational pharmaceutical companies.
The company has received certificates for the management system, ISO 9001:2015, and ISO 14001:2015 from ROHS Certification Private Limited.
As of July 31, 2024, the company has 175 employees across various departments.
Onyx Biotec Limited Financial Information (Restated)
Onyx Biotec Limited’s revenue increased by 35.99% and profit after tax (PAT) rose by 64.35% between the financial year ending with March 31, 2024 and March 31, 2023.
| Period Ended | 31 May 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 7,476.57 | 7,413.58 | 5,872.36 | 3,683.84 |
| Revenue | 1,054.11 | 5,387.43 | 3,961.65 | 4,498.09 |
| Profit After Tax | 130.77 | 303.16 | 184.46 | 335.29 |
| Net Worth | 2,618.64 | 2,487.87 | 1,820.16 | 1,637.59 |
| Reserves and Surplus | 1,286.42 | 1,155.65 | 1,230.00 | 1,047.43 |
| Total Borrowing | 3,156.14 | 3,078.04 | 2,922.83 | 1,224.39 |
| Amount in ₹ Lakhs | ||||
Key Performance Indicator
The market capitalization of Onyx Biotec IPO is Rs 110.61 Cr.
KPI as of May 31, 2024.
| KPI | Values |
|---|---|
| ROE | 4.99% |
| ROCE | 3.71% |
| Debt/Equity | 1.21 |
| RoNW | 4.99% |
| P/BV | 3.1 |
| PAT Margin (%) | 12.42 |
Check Onyx Biotec IPO Peer Comparison here.
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 2.28 | 4.33 |
| P/E (x) | 26.81 | 14.1 |
Note:
- The Pre IPO EPS is calculated based on Pre issue shareholding as on date of RHP and the latest FY earnings as of March 31, 2024 that is available in RHP.
- The Post Issue EPS is calculated based on the Post issue shareholding and annualized FY earnings of May 31, 2024 that is available in RHP.
Objects of the Issue (Onyx Biotec IPO Objectives)
The Company proposes to utilize the Net Proceeds from the Issue towards the following objects:
- Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use;
- Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections;
- Prepayment or repayment of all or a portion of certain loans availed by the Company; and
- General Corporate Purposes.
Onyx Biotec IPO Review (May apply)
[Dilip Davda] The company is engaged in a highly competitive and fragmented segment of sterile water, dry power-syrup products. It marked inconsistency in its top lines for the reported periods. Highly fluctuating bottom lines raises eyebrows. Based on FY25 super earnings, the issue appears fully priced. Well-informed investors may park moderate funds for long term. Read detail review…
Onyx Biotec IPO Subscription Status (Bidding Detail)
The Onyx Biotec IPO is subscribed 9.95 times on November 14, 2024 7:29:59 PM (Day 2). The public issue subscribed 16.40 times in the retail category, 0.00 times in the QIB category, and 8.15 times in the NII category. Check Day by Day Subscription Details (Live Status) Reload Subscription
| Category | Subscription (times) | Shares Offered | Shares bid for | Total Application |
|---|---|---|---|---|
| QIB | 0.00 | 9,12,000 | 0 | 0 |
| NII* | 8.15 | 6,88,000 | 56,06,000 | 713 |
| Retail | 16.40 | 16,00,000 | 2,62,40,000 | 13,120 |
| Total | 9.95 | 32,00,000 | 3,18,46,000 | 13,833 |
*Market Maker portion is not included to NII/HNI.
Onyx Biotec IPO Prospectus
Onyx Biotec Limited Contact Details
Onyx Biotec Limited
Bir Plassi Near Sainimajraropar,
Nalagarh Road
District Solan – 174101,
Phone: +91 172 265 6384
Email: generalinfo@onyxbiotec.com
Website: http://www.onyxbiotec.com/
Onyx Biotec IPO Registrar
Mas Services Limited
Phone: (011) 2610 4142
Email: ipo@masserv.com
Website: https://www.masserv.com/opt.asp